Abstract 4354
Background
Patients’ perception of clinical trials in Poland is mostly influenced by mass media. The image of CTs is often biased which may have an impact on recruitment.
Methods
Based on an anonymous 25-item Paper and Pencil Interview (PAPI) survey among 191 hospitalized oncological patients we analyzed knowledge, perception, willingness to participate and future expectations of CTs. Nominal scale: Yes/No/Don’t know, Likert scale of 0-5 points and multiple choice questions were applied.
Results
The majority of respondents were: (1) women: 70,2%, (2) people with secondary education: 57,6%, (3) at the age of 60-69: 41,9%, (4) living in cities over 100k inhabitants: 46,1%. Main findings 49,2% of respondents agreed to be enrolled in CTs; 15,3% refused and 35,4% were not certain. Among the driving factors for “YES” were: chance for a better/constant care - 76,3% and access to additional monitoring - 73,1%. 57,0% of respondents declared altruistic reason. The main reasons for not participating were: concern about toxicity - 62,1%, lack of efficacy - 55,2% and being a “guinea pig” - 41,4%. Among respondents uncertain about participation in CT, the factors of the highest impact on potential enrollment were: terminal phase of the disease/no other option: 68,7%/ 56,7%. The incentive of the family member or friend does not have a significant impact - only 19,4% respondents would follow it. Other findings 55,8%/ 54,7% of respondents do not know about the existence of any legal acts/state institutions that oversee CTs. 60,8% of respondents do not know whether there are independent bioethical committees that approve each CT prior to launch. 64,9% of respondents think that research funded by pharma companies is NOT as reliable as that of independent sources eg. medical universities. 76,2% of respondents think that the current amount of information on CTs is insufficient and 87,2% would like to know more.
Conclusions
The level of knowledge about CTs among patients is insufficient but the willingness to participate is high which is mainly driven by a possibility of a better and constant care. The trust in the pharmaceutical industry should be increased.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Kotowski: Full / Part-time employment: Roche Polska sp z o.o. All other authors have declared no conflicts of interest.
Resources from the same session
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract
1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4058 - 68Ga-PSMA guided bone biopsies for molecular diagnostics in metastatic castration resistant prostate cancer patients
Presenter: Anouk de Jong
Session: Poster Display session 3
Resources:
Abstract
2226 - Spatial-Temporal Change in Quantitative Total Bone Imaging (QTBI) and Circulating Tumor Cells (CTCs) in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide (ENZA)
Presenter: Glenn Liu
Session: Poster Display session 3
Resources:
Abstract
5795 - Efficacy of Enzalutamide in Hormone-sensitive Metastatic Prostate Cancer: Clinical Utility of 18F-Choline PET and Whole Body MRI.
Presenter: Susanne Osanto
Session: Poster Display session 3
Resources:
Abstract
899 - Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Presenter: Jungreem Woo
Session: Poster Display session 3
Resources:
Abstract
3094 - Circulating tumor cell (CTC) genomic landscape in neuroendocrine prostate cancer (NEPC) by single cell copy number analysis
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
2527 - Circulating Tumor Cells (CTC) count and Prostate-Specific Antigen (PSA) response measures in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients (pts) treated with Docetaxel (Doc)
Presenter: Rebeca Lozano Mejorada
Session: Poster Display session 3
Resources:
Abstract
6106 - Assessing the clinical relevance of drug–drug interactions (DDI) with darolutamide (DARO)
Presenter: Christian Zurth
Session: Poster Display session 3
Resources:
Abstract
2237 - KEYNOTE-921: phase 3 study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract